performed using TaqMan probes. Serum levels of thyroid autoantibodies, IL6 and IL17 were measured according to enhanced chemiluminescence (ECL) assay. Allele A of STAT3 SNP rs744166 A>G was significantly more frequent in both HT and GD patients, while allele G was significantly more frequent in the control group. Similarly, allele C and CC genotype of STAT3 SNP rs3816769 C>T were significantly more frequent in the control group in comparison to HT and GD patients. Significantly higher TgAb median values were associated with CT rs3816769 genotype in HT patients. Serum levels of IL6 and IL17 positively correlated with TPOAb in the HT group. Serum level of IL6 positively correlated with TPOAb in the AITD group. Both studied polymorphisms seem to play a significant role in susceptibility to AITD (HT and GD). STAT3 SNPs may influence TAb level in AITD patients.
INTRODUCTION
Autoimmune thyroid diseases (AITDs), which include Graves' disease (GD) and Hashimoto's thyroiditis (HT), are multifactorial diseases with a documented immunogenetic background. Among many immune-related genes, the role of signal transducer and activator of transcription (STAT) genes is underlined. STAT genes code immunoregulatory proteins and act in interaction with cytokine receptors as second messengers in the Jak/STAT signaling pathway. It was recognized that STATs after activation via phosphorylation, dimerization and translocation to the nucleus regulate expression of many target genes [1] . STATs influence the inflammatory response, angiogenesis, apoptosis and differentiation of cells. They also take part in functioning of the human immune system through proliferation and apoptosis of T lymphocytes [2] . Recently, it has been documented that STAT3 proteins transduce signals mainly from IL10 and IL6, influence differentiation of Th0 lymphocytes into Th17, and participate in IL17 secretion [3] . Therefore, it is claimed that STAT3 via IL6 and IL17 cytokines generates a signaling network playing a crucial role in development of autoimmune disorders, including AITD [4] . It was confirmed that deletion of the STAT3 gene in myeloid cells provokes inflammatory reactions [1] . The role of single nucleotide polymorphisms (SNPs) in the STAT3 gene (17q21 locus) was reported in autoimmune diseases, e.g. inflammatory bowel diseases (IBD) [5] [6] [7] . The most often described SNPs of the STAT3 gene related to autoimmunity and chronic inflammation are rs744166 (G>A) and rs3816769 (C>T). So far, only one study confirming an association between the STAT3 gene and AITD has been published [4] . The aim of our study is to evaluate the frequency of selected polymorphisms of STAT3 (rs744166 and rs3816769) in AITD patients in the Polish population. We also assessed the potential influence of study SNPs on the TAb production, and we evaluated the association between circulating proinflammatory cytokine levels (IL6 and IL17) and levels of thyroid autoantibodies in AITD patients.
MATERIALS AND METHODS
The Ethics Committee for Bioethics of the Medical University of Lodz, Poland (no. RNN/95/11/KE) approved the study protocol. Informed consent was obtained from all patients.
Genotyping
Total genomic DNA was isolated from blood samples using QIAamp DNA Mini Kit (Qiagen, Germany), according to the manufacturer's protocol. Quality and quantity of each DNA sample were assessed spectrophotometrically (NanoDrop Spectrophotometer ND-1000, Thermo Scientific, USA). SNP genotyping was performed using TaqMan probes (rs744166 and rs3816769) in the 7900HT Fast Real-Time PCR System using the TaqMan 5' allelic discrimination assay (Applied Biosystems, USA). Each sample was run in duplicate for each genotype analysis. The end-point readings were analyzed according to the manufacturer's instructions using SDS Software v. 2.4. 
Statistical analysis

RESULTS
STAT3 rs744166
Statistical analysis confirmed the presence of differences between the study groups (AITD, GD and HT) vs. the control group concerning the distribution of STAT3 SNP rs744166 genotypes and alleles. The results are summarized in Table 1 .
STAT3 SNP rs3816769
Following the statistical tendency, the allelic and genotypic distributions of STAT3 SNP rs3816769 were analyzed in AITD, HT and GD patients and compared with controls. The results are summarized in Table 2 .
Thyroid autoantibody levels -TPOAb, TgAb, TRAb STAT3 genotypes were correlated with TPOAb, TgAb and TRAb levels. The median values of TPOAb in patients with HT having CC genotype were insignificantly higher when compared to TT or CT patients. A significant difference in TgAb median values was seen when comparing individual genotypes: CT and CC or CT and TT. In the case of STAT3 SNP rs744166 polymorphism, patients having AA genotype revealed the highest TgAb and TPOAb median values. The results obtained for patients with HT are shown in Table 3 . In patients with GD, differences between thyroid autoantibody levels and STAT3 polymorphism were seen, although they were not significant. The results obtained for patients with GD are summarized in Table 4 .
Association between thyroid autoantibodies and IL6 in HT, GD and AITD TPOAb showed a significant positive correlation (P < 0.05) with serum IL6 in the HT group ( Fig. 1 ) and AITD group (Fig. 2) . In contrast, no association was found in the GD group (P = 0.062). Also, no significant association was observed between IL6 and TgAb in any group of patients or between IL6 and TRAb in the GD group. Association between thyroid autoantibodies and IL17 in HT, GD and AITD For each AITD patient group (HT and GD), TPOAb level and correlation with IL17 levels were assessed. TPOAb showed a significant positive correlation (P < 0.05) with serum IL17 in the HT group (Fig. 3) . No other significant correlation between TAb and IL17 was found. 
Linkage disequilibrium analysis
No linkage disequilibrium (LD) was found between the two studied polymorphic sites (P > 0.05, Fisher's exact test).
DISCUSSION
Although the exact etiopathology of AITD remains unknown, it is believed that AITD has an immunogenetic basis [8] [9] [10] . Thus, studies are performed to determine the functional effects of STAT3 polymorphism and its role in the inflammatory response and host defense. So far, published research shows that, firstly, STAT3 proteins mediate signals from proinflammatory cytokinesmainly IL10 and IL6. Secondly, they regulate differentiation of Th0 into subsets such as Th17, and influence IL17 expression in inflammatory tissue, in both in vitro and in vivo models [11] . Preferential production of IL17 is recognized as an important factor connected with autoimmune disease. It is documented that STAT3 proteins influence dysregulation of effector T cell responses, which represents a common feature of a wide range of autoimmune diseases. In light of published studies, STAT3 polymorphisms are associated with inflammatory bowel disease [5] [6] [7] , psoriatic arthritis [12] , ankylosis spondylitis [13] , multiple sclerosis (MS) [14] and asthma [15] . However, there is only one study concerning the impact of STAT3 polymorphism on AITD [4] . It involved a Chinese rather than Caucasian population and was focused on another STAT3 SNP 744166 polymorphism: C>T. According to that study, SNP rs744166 C>T showed a minimal impact on AITD, and no statistically significant difference between HT and GT subjects and the control group was observed. It should be pointed that our study is the first to examine two SNPs of the STAT3 gene and their impact on development of AITD in a European population. In the present study two SNPs in STAT3 were chosen, regarding their significant impact on increased risk of inflammatory disorders, as documented in several studies [5] [6] [7] .
In our study, we proved that allele A of STAT3 SNP rs744166 was significantly more frequent in both HT and GD patients in comparison to the control group, which indicates that allele A may increase HT and GD susceptibility (OR > 1). We also confirmed that allele G of STAT3 SNP rs744166 was significantly more frequent in the control group in comparison to the HT and GD group; however, its protective role was not exactly documented, considering OR < 1. Recently published studies of other authors documented STAT3 SNP rs744166 as a susceptibility marker of IBD. According to Cenit et al. [5] , the impact of STAT3 SNP rs744166 polymorphism on risk of ulcerative colitis (UC) and Crohn's disease (CD) development in Spanish patients is clear and indisputable. Similarly to our study, Ferguson et al. [6] documented that allele A of STAT3 SNP rs744166 was more frequent in patients with CD, although differences in allele A frequency between the CD and control group were not statistically significant. Opposite results to our study concerning the frequency of G and A allele of STAT3 SNP rs744166 were presented by Jakkula et al. [14] and Cenit et al. [12] . STAT3 SNP rs744166 was examined in patients with psoriatic arthritis and Behcet's disease in Spanish patients [12] . In the case of psoriatic arthritis patients, a significant association was seen between G allele and risk of disease. Jakkula et al. [14] presumed allele A of STAT3 SNP rs744166 as a protective factor in MS. The opposite results in psoriatic arthritis, MS and AITD may suggest population discrepancies. Interestingly, it was confirmed that some SNPs in the STAT3 gene (including intronic SNPs: rs744166 and rs3816769) and their haplotypes may be associated with genomic instability in the human population [7] . Additionally, it is supposed that both mentioned SNPs may influence many downstream target genes. Therefore, in our study we also focused on STAT3 rs3816769 C>T polymorphism in order to confirm its relationship with the risk of AITD development. According to our results, allele C and CC genotype of STAT3 SNP rs3816769 were significantly more frequent in the control group than in GD and HT patients. This may indicate that allele C and CC genotype have a protective role in HT and GD susceptibility. These results are similar to those obtained by
Ferguson et al. [7] . They proved a significant decrease in the frequency of C allele in CD patients from New Zealand and that individuals with CC or CT genotypes had decreased risk of CD as compared with TT homozygotes.
In addition to the analysis of correlation of both SNPs with risk of AITD, in our study we decided to evaluate whether these two SNPs (rs3816769 C>T and rs744166 A>G) reveal any influence on thyroid antibody levels and interleukin secretion. As mentioned earlier, STAT3 seems to be a vital part of the signaling network which if disturbed may lead to autoimmunity, increasing T-cell activation and production of autoantibodies. TPO and Tg are potential autoantigens. Elevated levels of TPOAb occur in 90% of cases of HT and 70% of GD, while elevated serum levels of TgAb occur in 70% of cases of HT and 30% of GD. Although levels of thyroid autoantibodies do not correlate with AITD disease activity, they are vital in diagnosis and prediction of relapse. In the present study we correlated, for the first time according to our knowledge, STAT3 SNPs and thyroid autoantibody levels. For HT patients, we found that median values of TPOAb were insignificantly (P > 0.05) higher in patients with CC genotype of STAT3 rs3816769 C>T SNP and median values of TgAb were significantly higher in patients with CT genotype of STAT3 SNP rs3816769.
Remarkably, in our study we recognized that allele C and CC genotype of STAT3 SNP rs3816769 may reduce the risk of AITD. On the other hand, HT patients with CC genotype were proved to have significantly high TPOAb median values. These controversial results may provide evidence that STAT3 SNP rs3816769 C>T has an indirect effect on the level of thyroid antibodies. Controversially, a direct functional impact of SNPs on the level of thyroid autoantibodies was confirmed in the case of the second study polymorphism: STAT3 SNP rs744166 A>G. Among HT patients having AA genotype (allele A was significantly more frequent in the HT vs control group) the highest TgAb and TPOAb median values were revealed. For GD patients differences between thyroid autoantibody levels and STAT3 SNP rs744166 A>G polymorphisms were seen, although they were not significant, probably due to the smaller number of participants. It should be pointed that the most important result shows that allele A of STAT3 SNP 744166 contributes to HT and GD susceptibility. Our innovative research confirms the potential functional effect of STAT3 SNP rs744166 A>G polymorphism and its role as a prognostic and diagnostic marker. Certainly, it needs more investigations in the future and larger groups of patients. Finally, we evaluated, for the first time, the effect of a particular STAT3 genotype and polymorphism on secretion of key AITD interleukins -IL6 and IL17. As mentioned, STAT3 signaling contributes to Th17 differentiation through cytokines, mainly IL6 [21, 3] . Recently, numerous studies have emphasized the role of Th17 and IL17 in autoimmunity -experimental autoimmune encephalitis [16, 17] , rheumatoid arthritis [18] , systemic lupus erythematosus [19] , psoriasis [20] , IBD [20] . Our results confirmed a significant correlation between IL6 and TPOAb in HT and AITD patients and a significant correlation between IL17 and TPOAb in HT patients. Such results may indicate that enhanced synthesis of IL17 is more specific for HT than GD patients and may be proposed as a diagnostic marker for HT in correlation with TPOAb. Moreover, elevated serum level of IL17 may indicate an imbalance between Th subsets and an excessive number of Th17 lymphocytes. IL6 is a well-known pleiotropic nonspecific proinflammatory cytokine described in many different inflammatory diseases, e.g. systemic lupus erythematosus [22] , renal and liver failure or neoplasia [23] , and also in AITD [24] [25] [26] . Here we correlated IL6 with TPOAb, which may clarify its exact role in pathogenesis of HT and AITD. Our observation confirmed the previous results of some authors [23, 27] , who highlighted the role of IL6 as a marker of the thyroid-destructive process in the absence of nonthyroidal illnesses. In conclusion, there is a paucity of research focusing on a combination of the STAT3 gene, thyroid autoantibodies and cytokine production; thus our study is worthwhile and should be continued, and the number of patients should be enlarged in the future. Moreover, we highlighted new aspects of AITD diagnosis and prediction of relapse. Thus, STAT3 is a target for Th17-dependent immunotherapy and a potential prognostic and diagnostic marker.
